Cobas Liat PCR system with four assays, 7/17
July 2017—Roche announced the CE-IVD launch of the Cobas Liat PCR System with four assays, including a 20-minute real-time PCR nucleic acid test to detect Clostridium difficile.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Liquid biopsy monitoring program for breast cancer, 7/17
July 2017—Cynvenio Biosystems announced the availability of ClearID Total Insight Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.
Assay for routine screening of CFTR gene, 7/17
July 2017—Swift Biosciences has commercially released its Accel-Amplicon CFTR Panel, which aims to provide research laboratories with a more comprehensive, next-generation sequencing–based approach to interrogate the coding region and select introns within the cystic fibrosis transmembrane conductance regulator gene for disease-relevant mutations and variants. The panel is designed to offer a higher resolution view into the CFTR gene and produces ready-to-sequence libraries in two hours.
Semi-motorized fluorescence microscope, 7/17
July 2017—Olympus’ new BX53 microscope features an LED illuminator equivalent to a 100-watt halogen lamp that delivers outstanding brightness and true-to-life images, according to the company. The LED enables researchers to clearly see purple, cyan, and pink dyes while its consistent color temperature aims to help speed up the observation workflow, since users don’t have to take time adjusting a color filter. The coded nosepiece works with the light intensity manager to automatically adjust the brightness level based on the objective being used.
Heparin calibration verification/linearity test kit, 6/17
June 2017—LGC Maine Standards’ Validate Heparin calibration verification/linearity test kit received FDA 510(k) clearance for use on Instrumentation Laboratory’s ACL TOP 500 hemostasis test systems. The Validate Heparin kit evaluates heparin anti-Xa activity in a human plasma matrix, is prepared using CLSI’s EP06-A recommended equal delta method for linearity testing, and is liquid, ready to use.
Cobas HPV assay, 6/17
June 2017—Roche announced the CE-IVD launch of Cobas HPV for use on the Cobas 6800/8800 Systems for cervical cancer screening. This HPV DNA assay gives laboratories the ability to run HPV DNA testing simultaneously with other previously released Cobas assays, including chlamydia and gonorrhea (CT/NG), HIV-1, HCV, HBV, CMV, and three next-generation assays for donor screening: the Cobas MPX, Cobas WNV, and Cobas HEV.
RNA-based biomarker panel for cancer, 6/17
June 2017—Cofactor Genomics launched its Pinnacle assay, which looks at gene fusions and gene expression in patient tumor samples to provide physicians with potential treatment targets for cancer patients.
CE mark for Singulex IVD platform, 6/17
June 2017—Singulex announced it received the CE mark for the Sgx Clarity system, a fully automated in vitro diagnostics platform powered by single-molecule counting technology. Up to 1,000 times more sensitive than existing technologies, single- molecule counting technology measures biomarkers at the lowest levels, revealing the presence, or absence, of disease so clinicians can provide the right treatment at the right time.
NeoGenomics, Definiens to develop novel assays, 6/17
June 2017—NeoGenomics and Definiens have expanded their alliance to develop and automate the analysis of new biomarker assays for clinical trials and routine clinical testing.
IHC imaging and analysis system, 6/17
June 2017—Applied Spectral Imaging introduced its HiPath imaging and analysis system, which provides computer-assisted PD-L1 interpretation for research use.